Skip to Content
Merck
  • Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen.

Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen.

Cell reports (2018-08-23)
Weston B Struwe, Elena Chertova, Joel D Allen, Gemma E Seabright, Yasunori Watanabe, David J Harvey, Max Medina-Ramirez, James D Roser, Rodman Smith, David Westcott, Brandon F Keele, Julian W Bess, Rogier W Sanders, Jeffrey D Lifson, John P Moore, Max Crispin
ABSTRACT

Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shield on native, virion-associated envelope glycoprotein (Env) spikes. The same bnAbs also bind to recombinant, soluble trimeric immunogens based on the SOSIP design. While SOSIP trimers are close structural and antigenic mimics of virion Env, the extent to which their glycan structures resemble ones on infectious viruses is undefined. Here, we compare the overall glycosylation of gp120 and gp41 subunits from BG505 (clade A) virions produced in a lymphoid cell line with those from recombinant BG505 SOSIP trimers, including CHO-derived clinical grade material. We also performed detailed site-specific analyses of gp120. Glycans relevant to key bnAb epitopes are generally similar on the recombinant SOSIP and virion-derived Env proteins, although the latter do contain hotspots of elevated glycan processing. Knowledge of native versus recombinant Env glycosylation will guide vaccine design and manufacturing programs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
DL-Dithiothreitol, ≥99.0% (RT)
Supelco
Discovery® Glycan SPE Tube, bed wt. 250 mg, volume 3 mL, pk of 54
Supelco
Discovery® Glycan SPE Tube, 5 g, volume 60 mL, pk of 16
Supelco
Discovery® Glycan SPE Tube, bed wt. 500 mg, volume 6 mL, pk of 30
Supelco
Discovery® Glycan SPE Bulk Packing, pkg of 50 g
Supelco
Discovery® Glycan SPE Tube, bed wt. 1 g, volume 12 mL, pk of 20